Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Dr. Mark Socinski covered the TAILOR trial, an Italian study directly comparing second line Taxotere (docetaxel) to Tarceva (erlotinib) in advanced NSCLC patients without an EGFR mutation, in the ASCO Lung Cancer Highlights program. However, as a preview to his comments you'll find in the podcast here, I'll share that he wasn't fond of the trial or the questionable value of the results from it.
Still, the trial is among the ones likely to be most discussed in the field of lung cancer from ASCO 2012, so it's worth hearing what it showed, along with an expert perspective of how to interpret it. Below, you'll find the audio and video versions of the podcast along with the transcript and figures.
Dr. Socinski ASCO LC Highlights 2012 TAILOR Trial Audio Podcast
Dr. Socinski ASCO LC Highlights 2012 TAILOR Trial Transcript
Dr. Socinski ASCO LC Highlights 2012 TAILOR Trial Figs
We'll finish Dr. Socinski's presentation of ASCO Highlights in Lung Cancer with his summary of some work in small cell lung cancer. Look for that soon.
Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: